Funding Details
- Awarder
- Inbox
- Date Award
- April 15, 2025
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
-
$21,500,000
Company Info
- Traction
- Significant progress in clinical evaluation of HRX-215 with impressive safety results in completed Phase I trials.
- Organizations Involved
- Wellington Partners, Vesalius Biocapital IV, Novo Holdings A/S, Boehringer Ingelheim Venture Fund, Coparion, High-Tech Gründerfonds, Ascenion GmbH
- Company Description
- HepaRegeniX is developing drugs for treating acute and chronic liver diseases.
- Market
- Liver diseases
- Location
-
Tuebingen,
Germany
- Coinvestors
- Wellington Partners
Links